Teriparatide Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: PepTools vendor-neutral scientific reference catalog

Recombinant peptide hormone; parathyroid hormone analog compound Reference needs_revision Best effort · source review pending

Also known as: (1-34)-human parathyroid hormone, 1-34-human PTH, human parathyroid hormone 1-34, PTH (1-34), LY-333334, LY333334, teriparatide recombinant human, teriparatide rDNA, teriparatida, teriparatidum

Open in Calculator ← Compound Index All Tools

Best-effort research profile: this record has not passed full two-source scientific verification. Descriptive fields, research protocols, storage/handling notes, and interaction guidance below are shown with their evidence labels, but calculator presets and exact dosing math remain hidden until the record is verified or reaches Community-Supported status.

Quick Facts

Reference Sizes

Not standardized / source review pending

Storage

For the labeled injection formulation: store refrigerated at 2–8 °C, do not freeze, minimize time outside refrigeration, and protect the cartridge from physical damage and light.

Best-Effort Research Profile

Teriparatide is a recombinant peptide hormone and parathyroid hormone analog comprising the first 34 N-terminal amino acids of the 84-amino-acid human parathyroid hormone. Its biological actions are mediated through high-affinity parathyroid hormone receptors. Intermittent systemic exposure stimulates new bone formation through preferential stimulation of osteoblastic activity over osteoclastic activity and influences calcium and phosphate metabolism.

Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.

Research Profile

Half-Life

Approximately 1 hour after subcutaneous administration.

Onset

Peak serum concentration occurs approximately 30 minutes after subcutaneous injection; serum concentrations decline to non-quantifiable levels within approximately 3 hours.

Administration Routes (Research)

subcutaneous

Reported Research Effects

Binds to high-affinity parathyroid hormone receptors and produces physiological PTH-like effects on bone and kidney.
With intermittent exposure, stimulates new bone formation on trabecular and cortical bone surfaces through preferential stimulation of osteoblastic activity.
Increases biochemical markers of bone formation, including bone-specific alkaline phosphatase and procollagen I carboxy-terminal propeptide.
Increases skeletal mass and bone strength in clinical studies.
Transiently increases serum calcium and decreases serum phosphorus after administration.

Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Notes

CommonSizes is left empty because commercially packaged pen sizes are formulation- and product-specific rather than general compound reference sizes. Solubility data for the neat peptide were not entered because a sufficiently authoritative, standardized value was not identified.

Supplementary research context only. Not medical advice or a treatment recommendation.

Registry Identifiers

Molecular formula: C181H291N55O51S2; molecular weight: 4117.8 Da; CAS RN: 52232-67-4; PubChem CID: 16133850; ChEBI: CHEBI:135983; FDA UNII: 10T9CSU89I; InChIKey: OGBMKVWORPGQRR-UMXFMPSGSA-N

Source-Backed Observations

Teriparatide is a 34-residue peptide identical in sequence to the biologically active N-terminal region of human parathyroid hormone. FDA labeling describes recombinant production using genetically modified Escherichia coli. The labeled injection formulation is a clear, colorless, isotonic solution adjusted to approximately pH 4.

Reflects published research. Educational reference — not a recommendation for use.

Sources Under Review

FORTEO (teriparatide injection) Prescribing Information, revised August 2026
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/021318s059lbl.pdf (accessed 2026-08-28)

Teriparatide, PubChem Compound Summary, CID 16133850
https://pubchem.ncbi.nlm.nih.gov/compound/16133850 (accessed 2026-08-28)

TERIPARATIDE, FDA UNII Record 10T9CSU89I
https://precision.fda.gov/uniisearch/srs/unii/10t9csu89i (accessed 2026-08-28)

Terrosa, INN-teriparatide, EPAR Product Information
https://www.ema.europa.eu/en/documents/product-information/terrosa-epar-product-information_en.pdf (accessed 2026-08-28)

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Reconstitution CalculatorConcentration, draw volume, per-unit amounts Unit Convertermg, mcg, mL, units conversion Compound CompareSide-by-side comparison tool Cost CalculatorCost per mg, mcg, per-draw

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.